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Abstract
In high malaria transmission settings, the use of sulfadoxine-pyrimethamine-based intermit-
tent preventive treatment during pregnancy (IPTp-SP) has resulted in decreased antibody
(Ab) levels to VAR2CSA. However, information of Ab levels in areas of low or intermediate
malaria transmission after long-term implementation of IPTp-SP is still lacking. The present
study sought to evaluate antibody prevalence and levels in women at delivery in Etoudi,
a peri-urban area in the capital of Yaounde´, Cameroon, that is a relatively low-malaria
transmission area. Peripheral plasma samples from 130 pregnant women were collected at
delivery and tested for IgG to the full-length recombinant VAR2CSA (FV2) and its most
immunogenic subdomain, DBL5. The study was conducted between 2013 and 2015,
approximately ten years after implementation of IPTp-SP in Cameroon. About 8.6% of the
women attending the clinic had placental malaria (PM). One, two or 3 doses of SP did not
impact significantly on either the percentage of women with Ab to FV2 and DBL5 or Ab lev-
els in Ab-positive women compared to women not taking SP. The prevalence of Ab to FV2
and DBL5 was only 36.9% and 36.1%, respectively. Surprisingly, among women who had
PM at delivery, only 61.5% and 57.7% had Ab to FV2 and DBL5, respectively, with only
52.9% and 47.1% in PM-positive paucigravidae and 77.7% of multigravidae having Ab to
both antigens. These results suggest that long-term implementation of IPTp-SP in a low-
malaria transmission area results in few women having Ab to VAR2CSA.
Introduction
In pregnant women, Plasmodium falciparum-infected erythrocytes (IE) express an antigen,
VAR2CSA, that participates in the binding of IE to chondroitin sulfate A (CSA) on the syncy-
tiotrophoblast lining the intervillous space of the placenta [1, 2]. The sequestration of IE in
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placental tissue results in the pathogenesis of placental malaria (PM). PM is an important risk
factor for maternal anemia and delivery of low birth weight babies [3, 4], which remains one of
the leading causes of mortality and morbidity in neonates and infants in sub-Saharan Africa.
Thus, preventing malaria in pregnant women is necessary not only to reduce maternal mor-
bidity but also to minimize the consequence of PM on the health of their offspring. Upscaling
of malaria control strategies, particularly effective case management with the use of rapid diag-
nostic tests, use of intermittent preventive treatment with sulfadoxine-pyrimethamine during
pregnancy (IPTp-SP), and insecticide-treated bed nets (ITN), have led to a worldwide reduc-
tion of malaria-related morbidity and mortality [5]. However, compliance with intervention
strategies together with the expanding resistance to anti-malarial drugs and insecticides pose a
great challenge. In addition, SP cannot be administered in women during the first trimester of
the pregnancy, although P. falciparum infection is also frequent and harmful during this
period [6]. The development of an effective vaccine against PM may offer a sustainable solu-
tion to protect mothers and their babies from malaria-related morbidity and mortality in
endemic areas.
As the major P. falciparum surface protein that mediates IE accumulation in the placenta
[7, 8], leading to inflammation, the VAR2CSA antigen is the main target of protective immu-
nity to PM. In many malaria endemic areas, exposure to malaria is perennial and pregnant
women acquire antibodies (Ab) to VAR2CSA over successive pregnancies that improve preg-
nancy outcomes [9, 10]. Previous studies reported that parasites with a VAR2CSA knock-out
gene irreversibly lose the ability to adhere to CSA [11], and that Ab to VAR2CSA inhibit IE
binding to CSA in vitro [12, 13]. This evidence strongly supports VAR2CSA as the leading can-
didate for a PM vaccine. The rationale for a PM vaccine is to induce immunological memory
to the IE with the VAR2CSA phenotype, and elicit an accelerated response upon subsequent P.
falciparum infections. Prior studies reported that high malaria transmission is required for nat-
ural acquisition of long-lasting Ab response to PM [14]. Thus, any variable that affects the risk
for P. falciparum exposure could influence the magnitude and the quality of Ab response to
the potential VAR2CSA-based vaccine. Although SP inhibits folic acid synthesis in malaria
parasites, which is required for parasite replication, decreasing thereby the exposure of preg-
nant women to P. falciparum antigens, conflicting data exist about the impact of IPT on Ab
response to VAR2CSA. In fact, the use of IPTp-SP has resulted in decreased Ab levels to
VAR2CSA in some high transmission settings [15, 16], while no impact of the treatment on
the Ab response was found in other lower malaria endemic areas [17,18]. This suggest that the
impact of IPT on Ab response to VAR2CSA changes across different geographic conditions.
The eco-epidemiological profile of malaria transmission in Cameroon is very heterogenic
and is made of three patterns (Sahelian, soudanian and equatorial), different by their malaria
transmission period and entomological indices [19]. Within a given pattern, some variation is
also observed; for example, in the equatorial pattern where this study was carried out, the
transmission increases from the center urban to rural areas. Available data on Ab response to
VAR2CSA in Cameroonian women exist only for central urban (low malaria transmission)
[20, 21] or rural area (high malaria transmission) [14, 15, 22, 23], although these areas are usu-
ally separated by a peri-urban or sub-urban area where malaria transmission is intermediate
or relatively low. In addition, most of previous studies on Ab response to VAR2CSA in Camer-
oon were carried out before the IPTp-SP implementation. The present study sought to evaluate
the prevalence of anti-VAR2CSA (FV2 and DBL5) Ab and levels of Ab in women at delivery
in Etoudi, a peri-urban area in the capital of Yaounde´, Cameroon, that is a relatively low-
malaria transmission area, after long-term implementation of IPTp-SP. The results of the
study will help to improve the design of future clinical trials in malaria endemic areas, on the
efficacy of the potential VAR2CSA-based vaccine against PM.
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Materials and methods
Ethical considerations
The study protocol was reviewed and approved by the National Ethics Committee of Camer-
oon (Ethical Clearance 2013/02/ N˚ 029/L/CNERSH/SP). Administrative Authorizations were
obtained from the Ministry of the Public Health of Cameroon (No D30-392 AAR/MIN-
SANTE/SG/DROS/ CRC/ CEA1) and from Health Centre. Participation in the study was vol-
untary with written informed consent from each woman. Upon collection, all samples and
clinical information about the mother and baby were de-identified. The study was performed
following the guidelines and regulations of human clinical research as recommended by the
Ministry of the Public Health of Cameroon. Malaria rapid diagnostic test (RDT) was per-
formed for each woman at the time of enrollment and positive results were reported to the
physician for prescription of treatment according to the national policy.
Study population and sample collection
This cross-sectional study was carried out between 2013 and 2015 at the Marie Reine Health
Center in Etoudi, situated in a peri-urban area of Yaounde´, Cameroon. Malaria transmission
in this area is relatively low and perennial, peaking in May (during the long-wet season from
March to June) and October (during short wet season from September to November). A total
of 130 HIV-negative women aged 16 to 39 years were recruited. Information on the mother’s
health, estimated length of pregnancy, parity, age, use of anti-malarial drugs, IPTp-SP usage,
HIV status, and baby birth weight were recorded. Peripheral blood samples were collected in
EDTA tubes from women immediately following delivery. A portion of the blood was used to
prepare thick and thin smears for microscopy and to measure hemoglobin levels. The remain-
der was centrifuged and plasma was collected and stored at -80º C for antibody studies. Placen-
tal tissues were also collected and a section excised to prepare impression smears and for
histology.
Diagnosis of placental malaria and determination of hemoglobin levels
Thick and thin blood smears, were prepared using Giemsa-Wright stain and read by two
skilled microscopists to determine the presence of malaria parasites. In addition, thin film of
peripheral blood was used to determine parasite species. Results from blood smears were com-
pared with RDT results obtained at enrollment using the CarestartTMHRP2 (Pf) (Access Bio
Inc. NJ, USA). Placental sections were fixed in buffered formalin, embedded, stained with
hematoxylin-eosin, and examined for IE and malaria pigments. Women were considered PM
+ if IE were detected in impression smears of villous tissue and/or in histological sections.
Hemoglobin levels in maternal blood were determined using a Coulter Counter (URIT-3300,
Europe).
Measurement of antibodies
Plasma IgG Ab levels to VAR2CSA recombinant proteins (FV2 and DBL5) of the FCR3 strain,
expressed in Baculovirus-transfected insect cells, were measured using a multi-analyte plat-
form (MAP). The coupling of the recombinant proteins to MagPix microspheres and basic
protocol have been described previously [21, 24, 25]. Briefly, 50 μl of antigen-coupled micro-
spheres (2000 microspheres/antigen) were incubated in a well of a microtiter plate (U-bottom
microplate) with 50 μl of plasma diluted to 1:100 in phosphate buffered saline containing 1%
bovine serum albumin (PBS 1% BSA) for 1 h at room temperature on a rotating shaker at 500
rpm (Microplate Shaker, Lab-line, Melrose Park, IL, USA). After washing twice with PBS-
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0.05% Tween 20 and once with PBS-1% BSA, 100 μl of secondary Ab (R-phycoerythrin-conju-
gated, Affini Pure F(ab0)2 fragment, Goat anti-human IgG Fc fragment specific, Jackson
Immunoresearch, West Grove, PA, USA) diluted to 2 μg/ml in PBS-1% BSA was added to
each well and incubated on a shaker in the dark for 1 h. Wells were washed and microspheres
re-suspended in 100 μl PBS-1% BSA. Plates were analysed immediately using MAGpix Analy-
ser (MAGpix Technology, USA). The reader was programmed to read a minimum of 100 beads
per spectral address, DD Gate 7500–15,000 and 35s timeout. The results were expressed as
median fluorescence intensity (MFI). Positive and negative controls were included on each
plate to control for plate-to-plate variation. Positive control was a pool of eight Cameroonian
multigravidae with high Ab levels to VAR2CSA. Negative controls were plasma from 12 Cam-
eroonian men, age 23 to 30 years of age, living in the study area. The cut-off value for seroposi-
tivity was determined based on the mean MFI + 2SD of the male samples.
Statistical analysis
Graph Pad Prism 6.0.1 was used for the statistical analyses. Continuous variables are reported
as means +/- standard deviations (SD) or medians with interquartile range (IQR). Differences
between groups were compared using unpaired t-test for normally distributed continuous
data or Mann-Whitney Rank Sum test for non-normal distributed continuous data, while cate-
gorical variables were reported as percentages and were compared using Fisher’s exact test. P
values<0.05 were considered statistically significant.
Results
Study population
The characteristics of women in this study are summarized in Table 1. Initially,105 women
were enrolled between June 2013 and February 2014, among whom 9 women had PM, provid-
ing an estimated prevalence of PM of 8.6% (9/105). Then, between May and June 2014, 25
women were enrolled to collect additional samples from PM+ women. Among the 25
Table 1. Characteristics of the study groups.
PM+ Women (n = 26) PM- Women (n = 104) P values�
Age in years (mean ±SD) 24.8 ± 5.2 26.5 ± 5.2 0.1311
Gravidity (mean ±SD) 2.6 ± 1.7 2.9 ± 1.7 0.3622
Parity (mean ±SD) 2.1 ± 1.1 2.5 ± 1.3 0.1770
Maternal hemoglobin in (g/dL) (mean ±SD) 10.6 ± 1.5 12.8 ± 1.18 <0.0001
Hematocrit (mean % PCV ±SD) 31.8 ± 4.9 38.7 ± 3.6 <0.0001
Percentage (%) of women with anemia 57.7 3.9 <0.0001
Peripheral parasitemia: IE/μl [median and 25%-75% IQR] 2889 [177, 66365] 0
Placental parasitemia (%) [median and 25%-75%IQR] 2.6 [0.1, 7.6] 0
Length of gestation (mean weeks ± SD) 39.2 ± 2.7 39.9 ± 2.36 0.3769
Baby birth weight (mean g ± SD) 3060 ± 471 3387 ± 526 0.0046
Percentage (%) of LBW babies 11.5 3.9 0.1425
Number of Doses of SP (mean ± SD) 1.6 ± 1.2 2.2 ± 1.1 0.0101
Percentage (%) women using ITNs�� 57.7 77.7 0.0482
�Analysis by PM status included: Student t test for normally distributed means; Mann Whitney for non-parametric medians (PCV); and Fisher’s Exact test for
comparisons of proportions.
�� Percentage of women who reported using insecticide treated bednets (ITNs). LBW: low birth weight; SP: sulfadoxine-pyrimethamine.
https://doi.org/10.1371/journal.pone.0237671.t001
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additional women, 17 were confirmed to have PM+, providing a total of 26 PM+ and 104 PM-
negative women in the study (total 130 pregnant women) (Table 1). Among the 26 PM
+ women, only 80% were peripheral blood-smear positive for malaria. The PM+ women
tended to be younger and pauciparous compared to PM- women, but their mean age, gravidity
and parity were not significantly different (age [24.8 vs. 26.5 years, p = 0.13]; gravidity [2.6 vs
2.9, p = 0.36] and parity [2.1 v 2.5, p = 0.18]) (Table 1). However, maternal hemoglobin levels
and hematocrits were significantly lower in PM+ compared to PM- women (hemoglobin 10.6
vs 12.8 g/dl and hematocrit 31.8 vs 38.7%, with both p values <0.0001) and the percentage of
women with anemia was higher in the PM+ group (57.7% vs 3.9%, p<0.0001). Among the 26
women with PM, a wide range in placental parasitemia was found (median parasitemia: 2.5%
with interquartile range of 0.1% to 7.6%). The mean baby birth weight in PM+ women was sig-
nificantly lower than that of PM- women (3,060 vs 3,387 g, p = 0.0046); although the percent-
age of low birth weight babies did not differ significantly between the groups (11.5 vs 3.9%,
p = 0.14). The mean number of IPTp-SP doses taken by PM+ women was lower than PM-
women (1.6 vs 2.2 doses, p = 0.01) and the proportion of women using bed nets was lower in
the PM+ group compared to PM- group (57.7 vs. 77.7%, p = 0.048). A comparison between
women who do not use IPT during pregnancy (n = 22) with women who took 3 doses (n = 70)
showed that women receiving 3 doses of SP were older (23.5 vs 26.5 years, p = 0.014), had
higher hemoglobin levels (11.8 g/dL vs. 12.8, p = 0.0048) and PCV (35.5% vs. 38.6%,
p = 0.005), and had fewer cases of placental malaria (31.8% vs. 5.8%, p = 0.0426).
Levels and prevalence of IgG Ab to VAR2CSA in PM+ and PM- women
Ab levels and the percentage of PM+ and PM- women who had Ab toVAR2CSA antigens
were investigated (Fig 1). For the 130 women, Ab levels to FV2 and DBL5 were higher in PM
+ women than PM- women (p = 0.0059 and 0.002, respectively) (Fig 1A and 1B). Furthermore,
when Ab levels were evaluated for only those women who were Ab-positive for FV2 and
DBL5, Ab levels remained significantly higher in the PM+ than PM- group (p = 0.0019 and
0.0079, respectively) (Fig 1C). At term, 61.5% and 57.7% of PM+ women had Ab to FV2 and
DBL5, respectively; whereas, only about half as many (31.7% and 30.8%) of PM- women had
Ab to these antigens (Table 2). Thus, high Ab levels were associated with infection and many
women lacked Ab to the VAR2CSA antigens.
Levels and prevalence of IgG Ab to VAR2CSA in women by gravidity status
Among PM+ women, the levels of Ab to FV2 and DBL5 did not differ significantly between
paucigravid and multigravid women (median: FV2: 10,459 vs 21,078 MFI p = 0.19; DBL5:
3,030 vs 24,450 MFI p = 0.10 (Fig 2). In addition, there was no difference in the prevalence of
Ab to FV2 (52.9% vs 77.8%, p = 0.40) or DBL5 (47.1% vs 77.8% p = 0.22). However, there was
a significant difference among PM- women, with multigravidae (MG) having significant
higher median Ab levels to FV2 and DBL5 (3,240 and 2,333 MFI) than paucigravidae (1,330
and 1,261 MFI respectively) (both p values�0.0001). Similarly, the percentage of PM- MG
women having Ab to FV2 and DBL5 (48.2% and 44.6%) was significantly higher than that of
paucigaviadae (12.5% and 14.6%, respectively) (p = 0.0001 and 0.0003, respectively) (Table 2).
Influence of use of SP on Ab levels and prevalence
The impact of IPTp-SP on Ab levels and percentage of women who were sero-positive at deliv-
ery for FV2 and DBL5 was assessed (Fig 3, Table 3). The use of two or three doses of SP did
not significantly impact either the percentage of women with Ab to FV2 and DBL5 or Ab levels
in Ab-positive women compared to women not taking or taking only one dose of SP.
PLOS ONE Antibodies to VAR2CSA and DBL5 in women receiving IPTp-SP
PLOS ONE | https://doi.org/10.1371/journal.pone.0237671 August 14, 2020 5 / 13
Fig 1. Antibody levels to VAR2CSA (FV2 and DBL5) in PM+ and PM+ women. Plasma Ab levels to VAR2CSA were
compared in women by PM status using Mann-Whitney Rank Sum test. A and B: IgG levels for all women (n = 130); C: IgG
levels for women who were Ab-positive (i.e., had levels higher than the cut-off (n = 49 women for FV2, n = 47 for DBL5); MFI:
median fluorescence intensity; IQR: interquartile range; Ab: antibodies; PM: placental malaria. The horizonal dotted lines
show the cut-off for Ab-positive, which was 4,483 MFI for FV2 and 3,232 MFI for DBL-5. Horizontal bars represent the group
median +/- 25% IQR.
https://doi.org/10.1371/journal.pone.0237671.g001
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Discussion
The present study sought to evaluate Ab prevalence and levels to VAR2CSA (FV2 and DBL5)
in women at delivery in Etoudi, a peri-urban area in Yaounde´, Cameroon, that is a relatively
low-malaria transmission area, after long-term implementation of IPTp-SP. The transmission
of malaria is decreasing in many parts of the world and Ab levels to P. falciparum antigens
may decline in the absence of boosting. Studies have reported that Ab levels to VAR2CSA
decreased in high transmission areas [15, 16] or remained unchanged in lower transmission
areas in women receiving IPT [17, 18]. Thus, investigations in areas with different malaria
transmission intensities are required, because the impact of IPT on the Ab responses changes
under different geographic conditions.
IPTp-SP has been implemented in Cameroon since 2004 and the coverage rate of IPTp-SP
(at least one dose of SP during pregnancy) is currently estimated at 30% in the rural areas and
70% in the urban areas [25]. In the current study, 83% of women took at least one dose of
IPTp-SP and 74% reported sleeping under a bed net during pregnancy, suggesting high com-
pliance to these preventive measures. Although it is recommended that all Cameroonian
women take at least three doses of SP during pregnancy (starting from the second trimester)
[26], SP is not free in some private health centers and is not prescribed for women taking some
drugs, such as cotrimoxazole. These reasons help explain why about 17% of women in this
study did not take SP. Compared to women who do not use IPTp-SP during pregnancy,
women taking 3 doses were older, had higher hemoglobin levels and PCV, and had fewer cases
of PM. Thus, IPT-SP is having a positive impact in Etoudi. This finding is in line with that of a
previous study that have reported an association between IPTp-SP usage and decrease of cases
of PM in Cameroonian women [15]. However, a small proportion (8/70) of women who took
the complete three-dose regimen of IPTp-SP still had P. falciparum infection. This could be
due to the presence of resistance to the drug as it has been reported in Cameroon [27], differ-
ences in the duration of SP half-life in the individual, or timing of treatment. Encouraging
pregnant women and clinicians to adhere to the new WHO policy that recommends the use of
SP at each prenatal visit after the first trimester [28] could further reduce the prevalence of pla-
cental malaria.
As expected, few women had Ab to FV2 and DBL5 in this low transmission area, where
IPTp-SP intervention has been used for>10 years. In fact, among the 104 PM- women at
delivery only 31.7% and 30.8% had Ab to FV2 and DBL5 respectively, and only 12.5% of pauci-
gravidae and 48% of MG had Ab to FV2 (Table 2). Although pre-IPT Ab prevalence in Etoudi
is unknown, Ab prevalence to FV2 in PM- women living in Yaounde´ prior to implementation
was 24.3% in pauci- and 40.1% in MG [20]. Thus, with decreased transmission and extended
use of IPT, today fewer women have Ab to FV2 during their first two pregnancies, but Ab
prevalence is similar in MG. Since the Ab response was higher in PM+ than PM- women (Fig
Table 2. Percentage of women with antibodies to VAR2CSA (FV2 and DBL5) at delivery by PM and gravidity status.
PM+ PM- P value�
FV2 16/26 (61.5%) 33/104 (31.7%) 0.0067
DBL5 15/26 (57.7%) 32/104 (30.8%) 0.0131
Pauci MG P value� Pauci MG P value�
FV2 9/17 (52.9%) 7/9 (77.8%) 0.3989 6/48 (12.5%) 27/56 (48.2%) 0.0001
DBL5 8/17 (47.1%) 7/9 (77.8%) 0.2167 7/48 (14.6%) 25/56 (44.6%) 0.0003
�Fisher exact test was used for comparison between paucigravidae and multigravidae. The results are presented as percentage. The cut-off for Ab-positive was 4,483 MFI
for FV2 and 3,232 MFI for DBL5. Pauci: paucigravidae; MG: multigravidae
https://doi.org/10.1371/journal.pone.0237671.t002
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Fig 2. Antibody levels to VAR2CSA (FV2 and DBL5) in paucigravid and multigravid women. Plasma levels of Ab to VAR2CSA were
compared between paucigravidae and multigravidae using the Mann-Whitney Rank Sum test. A and B: IgG Ab levels for all women
(n = 130); C: IgG levels for women with Ab levels higher than the cut-off (i.e., results for only Ab+ women) (n = 49 women for FV2,
n = 47 women for DBL5); MFI: median fluorescent intensity; IQR: interquartile range; Pauci: Paucigravid women; MG: Multigravid
women; Ab: antibody; Cut-off for Ab-positive was 4,483 MFI for FV2 and 3,232 MFI for DBL5. Horizontal bars represent the group
median +/- 25% IQR.
https://doi.org/10.1371/journal.pone.0237671.g002
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Fig 3. Influence of number of doses of SP on Ab levels to VAR2CSA (FV2 and DBL5) at delivery. Mann-Whitney Rank Sum test
was used to compare median plasma Ab levels to VAR2CSA between groups. A and B: IgG levels for all women (n = 130). C and D:
IgG levels for Ab-positive women (n = 45 women for FV2, n = 47 women for DBL5). MFI: median fluorescence intensity; IQR:
interquartile range; Ab: antibody; The cut-off for Ab-positivity was 4,483 MFI for FV2 and 3,232 MFI for DBL5. Horizontal bars
represent the group median +/- 25% IQR.
https://doi.org/10.1371/journal.pone.0237671.g003
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1), Ab to these pregnancy-associated antigens are a marker of infection and not protection.
One of the more relevant findings of this study is that Ab prevalence was similar in paucigravi-
dae (1 to 2 pregnancies) and MG (3 or more pregnancies) who have PM to FV2 (52.9% vs
77.8%, p = 0.40) or DBL5 (47.1% vs 77.8% p = 0.22). Thus, even when parasites were seques-
tered in the placenta, many women lacked Ab to VAR2CSA at delivery. In addition, the differ-
ence in Ab levels between pauci- and multi-gravidae was not significantly different (median:
FV2: 10,459 vs 21,078 MFI p = 0.19; DBL5: 3,030 vs 24,450 MFI p = 0.10, respectively (Fig 2).
The combined data suggest that some MG women had not become infected during previous
pregnancies due to low malaria transmission and the use of IPT-SP and produced either a pri-
mary or weak secondary Ab response during the current pregnancy; whereas, other MG pro-
duced higher levels of Ab (Fig 2), although the difference was neither statistically significant
nor robust enough to eliminate IE sequestered from the placenta. The absence of Ab in low
transmission areas suggests that VAR2CSA is not highly immunogenic and that i) repeated
exposure is needed to induce a strong Ab response to VAR2CSA and/or ii) Ab to other malar-
ial antigens help control parasitemia [20]. Since few women in Etoudi have high Ab levels to
VAR2CSA, a VAR2CSA vaccine would be beneficial not only to primigravidae, but to multi-
gravidae as well.
In this study, over 38% of women who had PM failed to produce Ab to FV2 and DBL5
(Table 2). Since IE were sequestered in the placenta, the question becomes, why didn’t they
produce detectable Ab to VAR2CSA? Several explanations seem feasible. First, some of the
women may have become infected too close to delivery to have produced Ab. However, since
malaria transmission was perennial and over one-third of PM+ women lacked Ab, one would
expect most women to be infected prior to the last 2–3 weeks of pregnancy. Second, the SP
may have reduced or eliminated malarial parasites to levels below that required to induce an
immune response. However, since Ab levels in women receiving 0–1 doses versus 2–3 doses
had similar Ab levels (Fig 3) and prevalence (Table 3), this explanation does not entirely
answer the question. Thirdly, IPTp-SP could result in very low, persistent levels of VAR2CSA
that induce T-reg responses. Fourthly, in this study, only the FcR3 allelic form of VAR2CSA
was used. Since VAR2CSA is a polymporphic protein [29], it is possible that women have Ab
to variants of FV2 or DBL5 that were not detected. Finally, multiple infections might be
required to induce a sustainable immune response to VAR2CSA. In support of this possibility
are data from a study conducted in Yaounde´ (low transmission) and Ngali II (high transmis-
sion) [22]. In a cohort of women who are either slide- or PCR-positive for P. falciparum before
6 months of pregnancy, at delivery only ~32% primi- and 40% multi-gravidae in Yaounde´
compared to 80% of primi- and>90% of multi-gravidae in Ngali II had Ab to FV2 at delivery
[14]. Thus, multiple infections during pregnancy may be needed to boost the response, and
the level of exposure is not sufficient in lower transmission areas or when IPTp-SP is used. No
matter what the explanation, not all women who have PM make Ab to VAR2CSA. Determin-
ing why they don’t, could be of value for designing a vaccine for preventing PM.
Table 3. Percentage of women with antibodies to VAR2CSA (FV2 and DBL5 FCR3) at delivery by use of IPTp-SP.
0–1 Dose 2–3 Doses p value�
n = 36 n = 94
FV2 10/36 (27.8%) 35/94 (37.2%) 0.4104
DBL-5 10/36 (27.8%) 37/94 (39.4%) 0.3377
�Comparison between women who received 0–1 dose and 2–3 doses of SP. The results are presented as percentage.
Fisher exact test was used. The cut-off for Ab-positivity was 4,483 MFI for FV2 and 3,232 MFI for DBL5.
https://doi.org/10.1371/journal.pone.0237671.t003
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Many questions remain about the impact of IPT-SP on acquisition of immunity to PM. In
the current study, PM was diagnosed by detecting infected erythrocytes in the intervillous
space of placenta. Thus, some women in the PM- group could have had submicroscopic infec-
tions that might have boosted their Ab response [30]. Although Ab detected in this study rec-
ognized FV2 and DBL5, it is unclear if they are able to block the binding of IE to CSA.
VAR2CSA is a polymorphic protein and the FcR3 variant used in this study may not be the
predominant strain current circulating in Etoudi. Since functional Ab to placental parasites
are variant dependent [31], a number of molecular, immunological and epidemiological stud-
ies are needed before a complete understanding of the role of VAR2CSA is determined and
how IPT-SP alters the natural response to this important antigen.
Conclusion
The results of this study suggest that long-term implementation of IPTp-SP in a relatively low-
malaria transmission area results in few women having Ab to VAR2CSA and Ab levels remain
low in those with and without PM.
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